First-in-humans phase I trial of O 304.
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2015
At a glance
- Drugs O 304 (Primary)
- Indications Diabetic complications; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Peripheral arterial disorders; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Betagenon
- 02 Feb 2015 According to Betagenon media release, status changed from recruiting to completed.
- 12 Mar 2014 New trial record